BD announced the results of a new survey revealing that 74% of women in Canada have delayed a gynecology visit, with 83% wanting more accessible and less invasive cervical cancer testing options, including at-home self-collection for human papillomavirus (HPV) tests.
BD announced today Health Canada approval of the BD Onclarity™ HPV Assay for human papillomavirus (HPV) testing for the use of self-collected vaginal specimens at home.
Mackenzie Health recently launched BD Alaris™ EMR Bidirectional Interoperability, which allows for two-way information flow between an IV pump and a patient’s electronic medical record.
Humber and BD are working together to reshape the landscape of health care workforce development and address the evolving needs of the industry along with health human resources.
BD-Canada is aware of the U.S. FDA issuing Safety Communication stating concern that certain plastic syringes may not provide consistent and adequate quality or performance.
The kidney care community advocates for more cost-effective treatment options, which offer a better quality of life and improved outcomes, although several obstacles hinder significant progress in improving kidney failure treatment.
Cervical cancer is one of the few cancers that is almost completely preventable through systematic screening programs, early detection with HPV testing and vaccination. Our generation holds the incredible potential to seize the opportunity to eradicate cervical cancer within our lifetime.
London Health Sciences Centre (LHSC) and St. Joseph’s Heath Care London (St. Joseph’s) are celebrating the installation of a Total Laboratory Automation (TLA) system within the clinical microbiology laboratory.
The program led by 19 to Zero aims to support point-of-care testing needs beyond COVID-19 for urban and rural communities in Alberta through education and diagnosis at clinics.
BD announced that it had received Authorization under the Interim Order from Health Canada for a new molecular diagnostic combination test for SARS-CoV-2, Influenza A and B and Respiratory Syncytial Virus (RSV) to help combat a potential “tripledemic” in the upcoming respiratory virus season.
Beim PowerPICC SOLO™ 2 Katheter handelt es sich um eine Universal-Katheterlösung für die intravenöse Verabreichung von Flüssigkeit und Blut sowie für die Druckinjektion.
Der aktivierte Hyperlink kann zu einer Website eines Dritten führen oder Informationen enthalten, die nicht für den deutschen Markt bestimmt sind. Das Anklicken des Links kann es Dritten ermöglichen, Ihre Daten zu sammeln oder weiterzugeben. Wir haben keine Kontrolle über diese Websites Dritter und sind nicht für deren Datenschutzerklärungen verantwortlich. Wenn Sie diese Website verlassen, empfehlen wir Ihnen, die Datenschutzerklärungen jeder Website zu lesen, die Sie besuchen.
Wenn die Website von einem anderen BD-Unternehmen verwaltet wird, beachten Sie bitte, dass sie möglicherweise anderen Gesetzen und Richtlinien unterliegt und Produkte und Dienstleistungen anbietet, die vor Ort nicht verfügbar sind. Bitte wenden Sie sich an Ihre BD-Vertretung vor Ort, wenn Sie Fragen haben oder weitere Unterstützung benötigen.
